Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II step-wise, randomized, multicenter, double-blind and controlled clinical trial to evaluate the safety and immunogenicity of a attenuated tetravalent lyophilized dengue vaccine manufactured by Butantan Institute. Three Clinical Sites at University of Sao Paulo - Brazil will participate in the study. A total of 300 volunteers will be recruited and divided into two steps: Step A (with no previous exposure to dengue) and Step B (with and without previous exposure to dengue). In step A the participants will be assigned to receive either the lyophilized vaccine, or the liquid vaccine(developed at NIH and produced and formulated at Butantan according to the NIH-Protocol), or the placebo. In Step B participants will be assigned to receive either the lyophilized vaccine, or the placebo. Both vaccine formulations (lyophilized and liquid) are composed of the same attenuated viruses: rDEN1∆30, rDEN2/4∆30(ME), rDEN3∆30/31, and rDEN4∆30. At the end of the study, 20 volunteers will have received the liquid formulation (NIH), 210 the lyophilized formulation (Butantan), and 70 will have received the placebo. All participants included in both steps will be followed by a period of five years after their inclusion in the study. The study hypothesis is that the investigational lyophilized dengue vaccine manufactured by Butantan Institute is safe and confers balanced immune response, after one dose of 1000PFU, to all for vaccine viruses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01436422

Dengue

COMPLETED PHASE1

Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults

NCT02021968

Dengue

COMPLETED PHASE1

Tetravalent Chimeric Dengue Vaccine Trial

NCT01110551

Dengue

COMPLETED PHASE1

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01506570

Dengue

COMPLETED PHASE1

Dengue Controlled Human Infection Model in Dhaka, Bangladesh

NCT05229354

Dengue

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase II step-wise, randomized, multicenter, double-blind and controlled clinical trial to evaluate the safety and immunogenicity of an attenuated tetravalent lyophilized dengue vaccine manufactured by Butantan Institute. A total of 300 volunteers will be recruited including men and no pregnant/breastfeeding women between 18 and 59 years of age complete, with and without previous exposure to dengue that will be randomized into Step A and Step B. Step A will include 50 volunteers with no previous exposure and they will be randomly assigned to receive one dose of either the lyophilized formulation (Butantan), or the liquid formulation (TetraVax-DV Vaccine - Admixture TV003 developed by NIH/NIAID and produced and formulated at Butantan according the NIH-Protocol), or the placebo. A second dose will be administered six months after the first vaccination as part of an exploratory assessment. Step B will include 250 participants(50 without previous exposure to dengue,and 200 with previous exposure to dengue) who will be randomly assigned to receive one dose of either the lyophilized formulation (Butantan),or the placebo. All participants included in both steps will be followed by a period of five years after their inclusion in the study. The vaccines will be administered at dose of 1000 PFU (for each of the vaccine viruses),and both vaccines and the placebo will be administered subcutaneously.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dengue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Step A: dengue lyophilized vaccine

Dengue 1,2,3,4 (attenuated) vaccine Two doses with a six-months interval, SC

Group Type EXPERIMENTAL

Dengue 1,2,3,4 (attenuated) vaccine

Intervention Type BIOLOGICAL

Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous

Step A:dengue liquid vaccine

TetraVax-DV Vaccine - Admixture TV003 Two doses with a six-months interval, SC

Group Type ACTIVE_COMPARATOR

TetraVax-DV Vaccine - Admixture TV003

Intervention Type BIOLOGICAL

Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous

Step A: Placebo

Placebo comparator Two doses with a six-months interval, SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Route:subcutaneous

Step B: dengue lyophilized vaccine

Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC

Group Type EXPERIMENTAL

Dengue 1,2,3,4 (attenuated) vaccine

Intervention Type BIOLOGICAL

Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous

Step B: Placebo

Placebo comparator Single dose, SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Route:subcutaneous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dengue 1,2,3,4 (attenuated) vaccine

Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous

Intervention Type BIOLOGICAL

TetraVax-DV Vaccine - Admixture TV003

Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous

Intervention Type BIOLOGICAL

Placebo

Route:subcutaneous

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Butantan DV Dengue Tetravalent Vaccine - Lyophilized formulation Dengue Tetravalent Vaccine - Liquid formulation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults (men and non-pregnant women), from 18 to 59 years old;
* Willingness to participate throughout the study period (approximately five years);
* Willingness to participate documented by the signature of ICF;
* Females with childbearing potential must be willing to avoid pregnancies up to three weeks after the last vaccine dose. All female volunteers will be considered with childbearing potential unless they have documented history of hysterectomy, tubal ligation or are postmenopausal (12 months of amenorrhea after the last menstrual period).

Exclusion Criteria

* Pregnancy (confirmed by positive beta-hCG test) or breastfeeding;
* Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history, physical examination and/or laboratory results;
* Compromised immune system diseases including: diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases;
* Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements;
* Values of absolute neutrophil, alanine aminotransferase (ALT) or serum creatinine count greater than or equal to Grade 1, as defined in the protocol;
* Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history;
* History of severe allergic reactions or anaphylaxis;
* Diagnosis of asthma with a history of hospitalization in the last six months due to illness;
* Fever or suspect fever within 72 hours prior to vaccination or axillary temperature greater than 37,8°C on the day of vaccination;
* Positive result of HIV-1 serology by screening or confirmed tests;
* Screening or confirmed positive test for hepatitis C virus (HCV);
* Positive test of hepatitis B virus antigen surface (AgHBs) alone or against hepatitis B "core" antigen antibody (anti-HBc);
* Use of corticosteroids (except topical or nasal) or other immunosuppressive drugs within 42 days before study initiation/baseline. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥10 mg of prednisone per day for over 14 days;
* Use of anticoagulant medication;
* Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization during the first 42 days after receiving the investigational product;
* History of asplenia;
* Have received blood products in the past six months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the first 42 days after vaccination;
* Use of any investigational product within 42 days before or after receiving this study vaccination;
* Has participated in another clinical trial six months prior to vaccination;
* Denies permission for biological material storage for future research as defined in ICF;
* Any other condition that might put in risk the safety/rights of a potential participant or hurdle his/her compliance with this protocol in investigator's opinion or his representative physician.

Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes